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The glutamate excitotoxicity, mediated throughN -methyl-d-aspartate receptors (NMDARs),
plays an important role in cerebral ischemia injury. Transient receptor potential vanilloid 4
(TRPV4) can be activated by multiple stimuli that may happen during stroke. The present
study evaluated the effect ofTRPV4 activation on NMDA-activated current (INMDA) and that
of blockingTRPV4 on brain injury after focal cerebral ischemia in mice.We herein report that
activation of TRPV4 by 4α-PDD and hypotonic stimulation increased INMDA in hippocampal
CA1 pyramidal neurons, which was sensitive toTRPV4 antagonist HC-067047 and NMDAR
antagonist AP-5, indicating that TRPV4 activation potentiates NMDAR response. In addi-
tion, the increase in INMDA by hypotonicity was sensitive to the antagonist of NMDAR
NR2B subunit, but not of NR2A subunit. Furthermore, antagonists of calcium/calmodulin-
dependent protein kinase II (CaMKII) significantly attenuated hypotonicity-induced increase
in INMDA, while antagonists of protein kinase C or casein kinase II had no such effect, indicat-
ing that phosphorylation of NR2B subunit by CaMKII is responsible for TRPV4-potentiated
NMDAR response. Finally, we found that intracerebroventricular injection of HC-067047
after 60 min middle cerebral artery occlusion reduced the cerebral infarction with at least
a 12 h efficacious time-window. These findings indicate that activation of TRPV4 increases
NMDAR function, which may facilitate glutamate excitotoxicity. Closing TRPV4 may exert
potent neuroprotection against cerebral ischemia injury through many mechanisms at least
including the prevention of NMDAR-mediated glutamate excitotoxicity.
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INTRODUCTION
Stroke is a worldwide health problem leading to high rates of death
and neurological disability in adults. The mechanisms underlying
cerebral ischemia injury are complex, but the intracellular free
calcium ([Ca2+]i) overload has been proved to play a vital role
(Szydlowska and Tymianski, 2010). It is generally accepted that
during cerebral ischemia, a large amount of glutamate accumu-
lates in the synaptic cleft, which results in excessive calcium influx
through N -methyl-d-aspartate receptors (NMDARs), to trigger
and eventually induce cell death (Paschen, 1996). The glutamate
excitotoxicity has long been recognized, however, treatment by
directly targeting glutamate receptors has failed in clinical trials
either because of intolerable side effects or lack of medical efficacy
(Kemp and McKernan, 2002).
Apart from neuronal death, another critically important patho-
physiological process in ischemic stroke is the formation of brain
edema which includes the cytotoxic and vasogenic edema (Simard
et al., 2007). The cytotoxic edema is the initial phase, which is
caused by the energy failure leading to intracellular fluid accumu-
lation. With ongoing of ischemia and reperfusion, cytotoxic edema
becomes progressively evident and the secondary vasogenic edema
eventually develops due to the disruption of blood-brain barrier
(BBB). Brain edema is not only an important pathological process
during cerebral ischemia, but also contributes to the adverse out-
come (Marmarou, 2007; Simard et al., 2007). Therefore, preven-
tion of brain edema or alleviation of brain edema-induced injury
is critical for the treatment of cerebral ischemia.
Recently, there is accumulating evidence concerning the
involvement of Transient Receptor Potential (TRP) channels, a
potentially important calcium influx pathway, in cerebral ischemia
injury. For example, TRP melastatin (TRPM) members, especially
TRPM2 and TRPM7, are important contributors to the neuronal
death following ischemia (Sun et al., 2009; Bai and Lipski, 2010).
Besides TRPM channels, other TRP family members might also be
responsible for ischemic neuronal injury. Among them, TRP vanil-
loid 4 (TRPV4) is attracting more and more attention because it
can be activated by multiple stimuli including hypotonic stimula-
tion, cell swelling, mild heat (>24-37˚C), arachidonic acid (AA),
and its metabolism epoxyeicosatrienoic acids (EETs; Plant and
Strotmann, 2007), some of which may happen during stroke.
TRPV4 is widely expressed in the central nervous system, includ-
ing hippocampus, cortex, thalamus, and cerebellum etc. (Kauer
and Gibson, 2009). During ischemia, the energy failure results in
cytotoxic edema and membrane lipid metabolism disorder caus-
ing extra release of free AA (Westerberg et al., 1987; Marmarou,
2007; Simard et al., 2007). Therefore, it is very likely that TRPV4
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is hyper-activated during ischemia, leading to an increase in cal-
cium influx. Blockage of TRPV4 by lowering temperature may
be responsible for the neuroprotection against oxygen-glucose
deprivation-induced injury (Lipski et al., 2006). TRPV4 block-
ers GdCl3 and ruthenium red increase the viability of astrocytes
exposed to oxidative stress (Bai and Lipski, 2010). But for the
lack of selectivity of these blockers, the role of TRPV4 in cerebral
ischemia injury remains to be determined. HC-067047 is recently
described as a potent and specific TRPV4 antagonist. It is reported
that HC-067047 can inhibit mouse TRPV4 activation by various
stimuli, including heat, hypotonic stimulation, AA, 4α-PDD, etc.
(Everaerts et al.,2010). The selectivity of HC-067047 makes it more
promising and possible to explore the involvement of TRPV4 in
cerebral ischemia.
Hippocampus is highly susceptible to ischemia among brain
regions and pyramidal neurons of CA1 region are most sensitive
to ischemia damage (Schmidt-Kastner and Freund, 1991). Con-
cerning that the entry of Ca2+ through NMDAR is the major
pathway leading to excitotoxic cell death associated with ischemia,
the present study firstly tested the effect of TRPV4 activation on
NMDA-activated current (INMDA) in hippocampal CA1 pyra-
midal neurons and then explored the mechanisms underlying
TRPV4-action. We also tested the effect of HC-067047 on brain
infarction in focal cerebral ischemia model mice.
MATERIALS AND METHODS
ANIMALS
Male mice (ICR, Oriental Bio Service Inc., Nanjing) were used
in the study. Care of animals conformed to standards established
by the National Institutes of Health. All animal protocols were
approved by the Nanjing Medical University Animal Care and Use
Committee (ID: 20110628). All efforts were made to minimize
animal suffering and to reduce the number of animals used.
SLICE PREPARATION
Mice (3-week-old) were decapitated under deep anesthesia with
ethyl ether. The brains were rapidly removed and the coronal brain
slices (400µm) were cut using a vibrating microtome (Microslicer
DTK 1500, Dousaka EM Co, Kyoto, Japan) in ice-cold modi-
fied artificial cerebrospinal fluid (mACSF) composed of (in mM)
NaCl 126, CaCl2 1, KCl 2.5, MgCl2 1, NaHCO3 26, KH2PO4 1.25,
and d-glucose 20 oxygenated with a gas mixture of 95% O2/5%
CO2. After 1 h recovery, hippocampal slices were transferred to a
recording chamber.
ELECTROPHYSIOLOGICAL RECORDING
Whole-cell patch clamp recording were performed at room tem-
perature (22–23˚C). Hippocampal neurons were viewed with
an upright microscope equipped with infrared-sensitive camera
(DAGE-MTI, IR-1000). INMDA was recorded using an EPC-10
amplifier (HEKA Elektronik, Lambrecht/Pfalz, Germany), sam-
pled at 10 kHz and filtered (Bessel) at 2.9 kHz. The capacitance and
series resistance were compensated more than 90%. Data obtained
from neurons in which uncompensated series resistance resulted
in voltage-clamp errors >5 mV were not taken in further analy-
sis. Liquid junction potentials were compensated before patching.
When the external solution was changed, measurements of the
changes in liquid junction potentials were <2 mV and were not
corrected.
The resistance of glass pipettes was 4–5 MΩ filled with the
pipette solution (in mM) CsCl 140, Tris-ATP 2, HEPES 10, EGTA
10 at pH 7.2. The slices were perfused continually with the oxy-
genated bath solution composed of (in mM) NaCl 74, CaCl2
2.5, KCl 2.5, NaHCO3 26, KH2PO4 1.25, d-glucose 20, and d-
mannitol 80 at osmolality of 300 mOsm/kg. When recording
INMDA, hippocampal pyramidal neurons were held at −60 mV.
NMDA together with glycine (10µM) were dissolved in bath solu-
tion and focally applied using a rapid drug delivery system directed
toward the soma of recorded neurons. One micrometer strychnine,
10µM bicuculline,10µM NBQX,and 0.1µM tetrodotoxin (TTX)
were added in bath solution to block glycine receptor, GABAA
receptor, AMPA receptor, and voltage-gated sodium channels,
respectively. When recording 4α-PDD-evoked current, 10µM 4α-
PDD and 0.1µM TTX were added in mASCF and a ramp protocol
depolarizing from −80 to +80 mV over 700 ms was used. Hypo-
tonic solution was obtained by adjusting the concentration of d-
Mannitol. The osmolality was measured using the Advanced Micro
Osmometer, model 3300 (Advanced instruments Inc., Norwood,
MA, USA).
DRUG TREATMENT
For intracerebroventricular (icv) implantation, mice (weighing
25–30 g) were anesthetized with chloral hydrate. A guide can-
nula (2.5 mm length, 23 gage) was implanted in the left lateral
ventricle. HC-067047 stock solution was freshly diluted with
0.9% sodium chloride on the day of experiment. HC-067047
(10µmol/2µl/mouse) was injected with a stepper-motorized
microsyringe (Stoelting, Wood Dale, IL, USA) at a rate of
0.5 ml/min. Control mice were given an equal volume of vehicle.
HC-067047 was firstly injected 4 h (HC-4 h), 8 h (HC-8 h), and
12 h (HC-12 h) after middle cerebral artery occlusion (MCAO),
respectively, and then injected every 8 h.
PREPARATION OF FOCAL CEREBRAL ISCHEMIA MODEL
Three days after cannula implantation, focal cerebral ischemia
was induced by MCAO as previously described (Mulcahy et al.,
2003). Briefly, after mice were anesthetized, a poly-l-lysine (0.1%,
weight/volume)-coated nylon monofilament thread (3/0 gage with
the tip heat blunted to a diameter of 0.104 mm) was inserted
through the external carotid artery and advanced into the inter-
nal carotid artery to occlude the origin of the middle cerebral
artery (approximately 12 mm). Adequacy of vascular occlusion
and reperfusion was monitored in the front parietal cortex of
the occluded side with a multichannel laser Doppler flow-meter
(Perimed PF5050, Sweden). Body and head temperatures were
controlled at 37± 0.5˚C with a thermostatically controlled heating
pad. Arterial blood pressure and gases were monitored through a
femoral catheter. After MCAO for 60 min, the filament was with-
drawn for reperfusion. Sham-operated (sham-op) animals were
treated identically, except that the MCAs were not occluded after
neck incision.
INFARCTION VOLUME MEASUREMENT
Brains were removed at 24 h post-MCAO, sectioned into five
equidistant coronal slices (2-mm-thick), and incubated with a 2%
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2,3,5-triphenyl-tetrazolium chloride (TTC) solution for 20 min
to visualize infarct tissue, using an image analysis software (NIH-
Image 3.12). Infarct volume was calculated as percentage of infarct
area to the contralateral hemisphere area in each slice.
CHEMICALS
4α-Phorbol-12,13-didecanoate (4α-PDD) was obtained from Cal-
biochem (San Diego, CA, USA) and TTX was obtained from Enzo
life Science (Ann Arbor, MI, USA). Others, unless stated, all came
from Sigma Chemical Company.
4α-PDD, HC-067047, d-Sphingosine, bisindolylmaleimide II
(BIM), TBB, DRB and KN62, NBQX, and strychnine were pre-
pared as stock solutions in DMSO. The final concentration of
DMSO in the bath chamber or pipette solution was<0.1%. KN93,
KN62, and d-Sphingosine were present in the pipette solution,
while d(−)-2-Amino-5-phosphonopentanoic acid (AP-5), ifen-
prodil, PEAQX tetrasodium hydrate (NVP-AAM007), 4α-PDD,
HC-067047, BIM, phorbol-12-myristate 13-acetate (PMA), TBB,
DRB, NBQX, strychnine, bicuculline, and strychnine were added
in bath solution.
DATA ANALYSIS
Data are expressed as means± standard error and were analyzed
with PulseFit (HEKA Elektronik) and Stata 7.0 software (STATA
Corporation, USA). In the present study, after testing the effect
of 4α-PDD and hypotonicity on INMDA, 10µM 4α-PDD was
applied to the same neuron to test whether the neuron had TRPV4
receptors. All data came from the neurons where 4α-PDD-evoked
current could be recorded. Before data analysis, both normality
of the distribution and homogeneity of variance were assessed
and data transformation (logarithmic or square root transforma-
tion) was considered whenever necessary. Paired or unpaired t -test
and ANOVA followed by Bonferroni’s post hoc test were used for
statistical analysis with the significance level set at P < 0.05. In
dose-response curve, INMDA induced by different dose of NMDA
was normalized to INMDA induced by 300µM NMDA in isotonic
solution (300 mOsm/kg) in the same neuron. The data were fit-
ted to Logistic equation in which I = Imax/[1+ (EC50/C)n], with n
being Hill coefficient and EC50 being the concentration producing
50% maximal response. When exploring current-voltage relation-
ship (I -V curve), INMDA induced at different holding potential was
normalized to INMDA with the holding potential being−60 mV in
isotonic solution in the same neuron.
RESULTS
4α-PDD INCREASES INMDA IN HIPPOCAMPAL CA1 PYRAMIDAL
NEURONS
As glutamate excitotoxicity is of great importance in cerebral
ischemia injury, we firstly explored whether TRPV4 activation
modulated NMDAR function. After application of 30µM NMDA
(for 20 s) and its co-agonist glycine onto hippocampal CA1 pyra-
midal neuron an inward current was recorded. This INMDA was
blocked by the specific NMDAR antagonist AP-5 (50µM),suggest-
ing its mediation by NMDAR (Figure 1B). Here, it was found that
INMDA was markedly increased by 31.6± 2.1% from -24.67± 1.04
to -32.33± 2.78 pA/pF after application of TRPV4 agonist 4α-
PDD (10µM) for 5 min (n= 10, paired t -test, P < 0.01). The
increase in INMDA was reversible after 4α-PDD was washed out
(Figure 1A). It was noted that in the presence of AP-5, 4α-PDD
almost had no effect on the current (n= 6, paired t -test, P > 0.05;
Figure 1B).
We then studied the effect of 4α-PDD on dose-response
curve of INMDA. EC50 and n values of dose-response curve were
19.91± 1.74µM and 1.74 in the absence of 4α-PDD, respectively.
After application of 4α-PDD, the maximal response to 300µM
NMDA was markedly increased (n= 6, paired t -test, P < 0.01),
but EC50 (19.93± 1.67µM) and n values (1.63) were almost
unaffected (unpaired t -test, P > 0.05 in each case; Figure 1C).
We also performed experiments on current-voltage relation-
ship of INMDA. Application of 4α-PDD markedly increased INMDA
at different voltages ranging from -80 to +60 mV. For exam-
ple, when the holding potential was -80 mV, INMDA was signifi-
cantly increased from -27.90 to -35.95 pA/pF (n= 8, paired t -test,
P < 0.01). In I -V curve of INMDA, the reversal potential was
9.61± 1.83 mV, which was not significantly different from the con-
trol (9.29± 1.58 mV; n= 8, paired t -test, P > 0.05). Besides this,
we also compared the ratio of current at +60/-80 mV to find that
the ration was not affected by 4α-PDD (control: -0.28; 4α-PDD:
-0.29, n= 8, paired t -test, P > 0.05; Figure 1D).
HYPOTONIC STIMULATION INCREASES INMDA IN HIPPOCAMPAL CA1
PYRAMIDAL NEURONS
As a cellular osmotic sensor, TRPV4 is sensitive to hypotonic
stimuli. Here, we tested the effect of hypotonic stimulation on
INMDA. When the external solution was changed from isotonic-
ity (300 mOsm/kg) to hypotonicity (240 mOsm/kg), INMDA was
increased by 39.0± 5.4% from -25.01± 2.71 to -34.13± 2.82
pA/pF (n= 17, paired t -test,P < 0.05; Figure 2A). The increase in
INMDA by hypotonic stimulation was largely reversible after hypo-
tonicity was washed out for 5 min. The increase in INMDA was
more evident with larger osmotic gradient (Figure 2E), and the
following experiments were performed using hypotonic stimula-
tion of 240 mOsm/kg which produced the significant increase in
INMDA.
As shown in Figure 2B, in the presence of AP-5, the cur-
rent was almost unaffected by hypotonic stimulation (n= 6,
paired t -test, P > 0.05). In hypotonic solution, the maximal
INMDA was significantly increased, but EC50 and n values of
dose-response curve were not markedly different in isotonic
and hypotonic condition (paired t -test, P > 0.05 in each case;
Figure 2C). Hypotonic stimulation increased INMDA at every volt-
age ranging from -80 to +60 mV, leaving the reversal potential
(control: 9.52± 1.31 mV; 240 mOsm/kg: 10.02± 1.56 mV, n= 9,
paired t -test, P > 0.05) and I (+60 mV)/I (-80 mV) ration unaf-
fected (control: -0.28; 240 mOsm/kg: -0.29, n= 9, unpaired t -test,
P > 0.05; Figure 2D). These results indicate that both 4α-PDD
and hypotonic stimulation have similar effect on INMDA.
THE SPECIFIC TRPV4 ANTAGONIST HC-067047 ATTENUATES 4α-PDD-
AND HYPOTONICITY-INDUCED INCREASE IN INMDA
HC-067047 is a recently discovered specific TRPV4 antago-
nist (Everaerts et al., 2010). The present study showed that
pre-application of HC-067047 (1µM) markedly attenuated the
increase in INMDA by both hypotonicity and 4α-PDD (unpaired
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FIGURE 1 | 4α-PDD increases INMDA in hippocampal CA1 pyramidal
neurons. (A)The typical recordings show that INMDA was increased from
−1.93 to −2.52 nA after application of 4α-PDD for 5 min and the current
recovered to −2.1 nA after washout. 4α-PDD-evoked current was recorded in
the same neuron. (B) INMDA was reduced from -25.13±2.01 to -2.05±0.77
pA/pF by AP-5 (n=6, paired t -test, P <0.01). Note that in the presence of
AP-5, the current was not changed by 4α-PDD. **P < 0.01 vs. 300 mOsm/kg
(C) Dose-response curves for INMDA before and during 4α-PDD application.
Each point represents the normalized current from 6 to 10 neurons. (D) I–V
curve was shown in the presence of and absence of 4α-PDD.
t -tests, P < 0.01 in each case; Figure 3). Combined with the above
results, it is suggested that activation of TRPV4 by either hypo-
tonicity or 4α-PDD enhances INMDA. The following experiments
were performed in isotonic and hypotonic solution to explore
the possible mechanisms underlying TRPV4-mediated increase in
INMDA.
NR2B SUBUNIT IS INVOLVED IN HYPOTONICITY-INCREASED INMDA
Functional NMDAR is composed of both an NR1 subunit, which
contains the glycine binding site, and an NR2 (A-D) subunit,which
binds to glutamate. In the adult brain, both NR2A and NR2B sub-
units are prominent in the hippocampus (Laurie et al., 1997).
In the presence of ifenprodil (10µM), a specific NR2B subunit
inhibitor, hypotonicity-induced increase in INMDA was markedly
attenuated (n= 33, unpaired t -test, P < 0.01; Figure 4A). By
contrast, pre-application of NVP-AAM007 (0.3µM), a specific
inhibitor of NR2A subunit, the increase in INMDA by hypotonicity
was unaffected (n= 29, unpaired t -test, P > 0.05; Figure 4B).
CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE II SIGNALING
PATHWAYS IS INVOLVED IN HYPOTONICITY-INCREASED INMDA
The NMDAR subunits possess phosphorylation sites for pro-
tein kinases that can modulate the function of NMDAR (Chen
and Roche, 2007). The following experiments were performed
to test whether Calcium/calmodulin-dependent protein kinase II
(CaMKII), protein kinase C (PKC), and casein kinase II (CKII)
pathways were responsible for hypotonicity-increased INMDA.
As CaMKII plays an important role in phosphorylation of
NMDAR,here we firstly evaluated the effect of CaMKII antagonists
KN62 and KN93 on INMDA in isotonic solution. Pre-incubation
of KN62 (5µM) or KN93 (5µM) decreased INMDA from -
25.50± 1.15 to -21.01± 2.71 pA/pF (n= 7,paired t -test,P < 0.05)
and from -25.08± 2.14 to -20.06± 1.56 pA/pF (n= 8, paired t -
test, P < 0.05), respectively. As shown in Figure 5A, with KN62
or KN93 in the pipette solution, INMDA was increased 8.5± 3.8%
(n= 15) and 8.7± 3.6% (n= 17) by hypotonicity, respectively,
both of which were significantly different from hypotonicity-
increased INMDA without antagonism of CaMKII (unpaired t -
test, P < 0.01 in each case). This result suggests that CaMKII is
responsible for the increase in INMDA caused by TRPV4 activation.
In isotonic solution, INMDA was increased from -24.42± 2.78
to -27.51± 0.84 pA/pF by PMA (agonist of PKC, 1µM; n= 6,
paired t -test, P < 0.05). After pre-application of PKC antagonists
d-Sphingosine (20µM) or BIM (1µM), INMDA was decreased
from -24.69± 0.94 to -21.63± 1.33 pA/pF (n= 9, paired t -test,
P < 0.05) and from -25.04± 1.55 to -22.63± 2.64 pA/pF (n= 7,
paired t -test, P < 0.05), respectively. Figure 5B shows that pre-
incubation of d-Sphingosine or BIM did not affect the increase in
INMDA by hypotonicity (unpaired t -test, P > 0.05 in each case).
We also tested the role of CKII signaling pathway, for this pathway
is reported to specially phosphorylate NR2B subunit. Here, it was
found that application of CKII antagonist TBB (10µM) or DRB
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FIGURE 2 | Hypotonic stimulation increases INMDA in hippocampal
CA1 pyramidal neurons. (A)The typical recordings show that INMDA
was increased from −1.73 to −2.42 nA when the extracellular isotonic
solution (300 mOsm/kg) was changed to hypotonic solution
(240 mOsm/kg) and the current recovered to −1.81 nA after washout.
4α-PDD-evoked current was recorded in the same neuron. (B) INMDA
was reduced from -25.74±3.12 to -2.67±0.87 pA/pF by AP-5 (n=6,
paired t -test, P < 0.01). Note that in the presence of AP-5, the current
was not changed by hypotonic stimulation. **P <0.01 vs.
300 mOsm/kg. (C) Dose-response curves for INMDA in isotonic and
hypotonic solution. Each point represents the normalized current from
7 to 17 hippocampal neurons. EC50 values were 19.23±1.89 and
18.24±1.07µM, and n were 1.71 and 1.79 for isotonicity and
hypotonicity, respectively. (D) I–V curves were shown in isotonic and
hypotonic solution. (E)The plot shows that hypotonic stimuli exhibited
more increase in INMDA with larger osmotic gradient.
FIGURE 3 |TRPV4 antagonist blocks 4α-PDD- and
hypotonicity-increased INMDA. (A) In the presence of HC-067047,
INMDA was almost not changed by hypotonic stimulation and the
increase in INMDA by hypotonicity was decreased from 39.0±5.4%
(n=17) to 4.1±2.2% (n=21). **P <0.01 vs. 240 mOsm/kg (B)
Pre-application of HC-067047, the increase in INMDA by 4α-PDD was
decreased from 31.6±2.1% (n=10) to 3.3± 3.1% (n=18).
##P <0.01 vs. 4α-PDD.
(100µM) decreased INMDA from -25.01± 5.95 to -18.19± 2.50
pA/pF (n= 7, paired t -test, P < 0.01), and from -24.94± 1.49 to
-17.16± 1.57 pA/pF (n= 7, paired t -test, P < 0.01), respectively.
Figure 5C shows that in the presence of TBB or DRB, INMDA
was increased 41.1± 4.0% (n= 24) and 40.2± 4.7% (n= 10)
by hypotonicity, respectively, both of which were similar to
the increase in INMDA by hypotonicity alone (unpaired t -test,
P > 0.05 in each case). These results indicate that neither PKC nor
Frontiers in Cellular Neuroscience www.frontiersin.org March 2013 | Volume 7 | Article 17 | 5
Li et al. TRPV4-mediated increase in NMDA-current
FIGURE 4 | NR2B subunit antagonist attenuates
hypotonicity-increased INMDA. (A) In the presence of ifenprodil, the
current was almost not changed by hypotonic stimulation and the
increase in INMDA by hypotonicity was markedly attenuated from
39.0±5.4% (n=17) to 3.8±1.8% (n=18). **P <0.01 vs.
240 mOsm/kg (B) Pre-application of NVP-AAM007, INMDA was increased
37.8±4.2% (n=14) by hypotonic stimulation, which was not different
from the increase by hypotonicity alone.
CKII signaling system is involved in TRPV4 activation-induced
increased INMDA.
TRPV4 ANTAGONIST REDUCES BRAIN DAMAGE AFTER FOCAL
CEREBRAL ISCHEMIA
The neuroprotection of blocking TRPV4 was tested in vivo using
MCAO mice to induce focal cerebral ischemia. Figure 6A shows
a representative experiment that the area of non-viable tissue, as
indicated by pale color, was much smaller (3.0± 1.8%, n= 10)
in the infracted hemisphere when mice were treated with HC-
067047 (HC-4 h), compared with the mice treated with vehicle
(35.3± 4.2%, n= 10; ANOVA followed by Bonferroni’s post hoc
test,P < 0.01). Furthermore, HC-067047, when was firstly admin-
istered 8 h (HC-8 h, 17.1± 5.8%, n= 10) or 12 h (HC-12 h,
18.2± 4.1%, n= 10) post-MCAO, could markedly reduce the size
of infarction (ANOVA followed by Bonferroni’s post hoc test,
P < 0.05 in each case; Figure 6B). These results suggest that block-
age of TRPV4 reduces MCAO-induced cerebral injury with an
efficacious time-window of at least 12 h.
DISCUSSION
Cytotoxic edema is an important pathological process as well
as a major cause of neuronal death in cerebral ischemia injury
(Marmarou, 2007; Simard et al., 2007). Activation of TRPV4 is
likely for its sensitivity to cell swelling, AA, and its metabolism
EETs, which are always associated with cerebral ischemia. Dur-
ing ischemia, glutamate-induced intracellular calcium overload,
which is mediated through NMDAR, plays an important role
in neuronal injury. In this study, we found that application of
4α-PDD or hypotonic stimulation enhanced INMDA in hippocam-
pal CA1 pyramidal neurons, which was markedly attenuated by
the specific TRPV4 antagonist HC-067047 (Figure 3), indicating
that activation of TRPV4 leads to the increase in INMDA. Addi-
tionally, 4α-PDD- or hypotonicity-increased INMDA was blocked
by NMDAR antagonist AP-5, indicating that TRPV4 potentiates
NMDAR response (Figures 1B and 2B). It is known that NMDARs
are calcium-permeable and the opening of these channels leads
to further membrane depolarization and greater calcium influx,
exacerbating intracellular calcium overload. Therefore, TRPV4-
induced enhancement of NMDAR response may helps to facilitate
glutamate-neurotoxicity during stroke.
The increase in INMDA probably results from an increase in
NMDAR expression or enhanced NMDAR function. The present
study mainly focused on the latter, for there is a report that
NMDAR subunits expression is unaffected in TRPV4 knockout
mice (Shibasaki et al., 2007). Although the maximal INMDA was
increased, EC50 value in dose-response curve was not changed
by either 4α-PDD or hypotonicity (Figures 1C and 2C), indi-
cating that TRPV4-action is not dependent on increasing ligand
binding affinity. Additionally, 4α-PDD and hypotonicity did not
change the reversal voltage or I (+ 60 mV)/I (−80 mV) ration in
I–V curve (Figures 1D and 2D), indicating that TRPV4-action is
voltage-independent. It has been demonstrated that NR2B subunit
is critical for a number of basic structural and functional attributes
associated with NMDAR (Loftis and Janowsky, 2003). In this study,
selective antagonism of NR2B but not NR2A subunit markedly
blocked hypotonicity-induced increase in INMDA (Figure 4), sug-
gesting the involvement of NR2B subunit in TRPV4-increased
INMDA. Increasing evidence supports the notion that the level of
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FIGURE 5 | CaMKII antagonists attenuate hypotonicity-increased INMDA.
(A) In the presence of KN62 or KN93, INMDA was almost not affected by
hypotonic stimulation and the increase in INMDA by hypotonicity was markedly
blocked by pre-application of KN62 or KN93. **P <0.01 vs. 240 mOsm/kg. (B)
INMDA was increased 36.2±4.0% (n=20) and 33.7±4.9% (n=12) by
hypotonic stimulation in the presence of d-sphingosine or BIM, respectively.
(C) Pre-incubation of TBB or DRB did not affect the increase in INMDA by
hypotonicity.
FIGURE 6 |TRPV4 antagonist reduces brain damage after focal cerebral
ischemia. (A) Representative photographs of cerebral infarction in MCAO
mice treated with HC-067047. Note that treatment with HC-067047 (HC-4 h)
after stroke significantly reduced the MCAO-induced cerebral infarction. (B)
Time-window of neuroprotective effect of HC-067047. Bar graphs show the
mean infarct volume percentage in MCAO mice that were treated with
HC-067047 starting 4, 8, and 12 h post-MCAO. **P < 0.01 and *P <0.05 vs.
vehicle-treated MCAO mice, #P <0.05 vs. HC-4 h.
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NR2B subunit phosphorylation is linked to the receptor activity,
leading to the prolonged calcium influx. Our previous studies have
reported that some intracellular signaling pathways are responsi-
ble for hypotonicity (TRPV4)-induced modulation on voltage-
gated ion channels and TRPV1 receptor (Liu et al., 2007; Chen
et al., 2008a,b, 2009; Li et al., 2011b). Here, CaMKII, PKC, and
CKII signaling pathways were selected for they are responsible for
phosphorylation of NR2B subunit (Chen and Roche, 2007). We
found that the increase in INMDA by hypotonic stimulation was
markedly attenuated by CaMKII, but not PKC or CKII antago-
nists (Figure 5). These results indicate that the phosphorylation
of NR2B subunit by CaMKII is responsible for TRPV4-induced
increase in INMDA. It is known that activation of CaMKII is nec-
essary before it phosphorylates NMDAR, which is dependence on
Ca2+/CaM. TRPV4 activation increased INMDA, which may facil-
itate calcium influx through NMDAR and exacerbate the increase
of [Ca2+]i. Mg2+, which mainly exists inside of cell in normal con-
dition, is very important for the activation of some kinases. The
present recording solution was lack of Mg2+, suggesting that this
recording condition may not be optimal condition for CaMKII
activity. However, activation of CaMKII was still possible, which
was caused by Mg2+ inside of neurons. Here, pre-application
of CaMKII antagonists KN62 and KN93 inhibited INMDA in
isotonic solution, which was consistent with the above deduc-
tion. It is reported that Ca2+/calmodulin-activated Ser-Thr kinase
(CASK), which functions as an active protein kinase even with-
out Mg2+ binding, may associated with CaMKII and modulate its
phosphorylation state (Mukherjee et al., 2008). Whether CASK
is involved CaMKII-induced modulation of NMDAR function
remains unclear in the present study. On the other hand, the C
terminus of TRPV4 contains a PDZ-binding-like motif that may
contribute to the interaction of TRPV4 with PDZ-domain proteins
(Garcia-Elias et al., 2008). Therefore, there may be other possibility
that TRPV4 per se influences the activation of CaMKII.
Another important result of this study is that we firstly pro-
vide in vivo evidence that closing TRPV4 exerts potent neuro-
protection against cerebral ischemic injury with at least a 12 h
efficacious time-window (Figure 6). In fact, over-activation of
TRPV4 may induce neuronal injury in cerebral ischemia through
multiple mechanisms. In cultured hippocampal pyramidal neu-
rons, application of glutamate induces more [Ca2+]i increase at
37˚C than at 25˚C, which is more evident in wild type neurons
than in TRPV4 knockout neurons. Moreover, this temperature-
dependent [Ca2+]i increase at 37˚C was markedly inhibited by a
NMDAR blocker in wild type but not in TRPV4 knockout neu-
rons, which indicates that TRPV4 activation promotes NMDAR
activation in hippocampal pyramidal neurons (Shibasaki et al.,
2007). Consistently, the present study showed that activation of
TRPV4 enhanced INMDA in hippocampal CA1 pyramidal neu-
rons. On the other hand, activation of TRPV4 can depolarize
the resting membrane potential (Shibasaki et al., 2007), which
helps the release of presynaptic glutamate. Our experiment per-
formed on the excitatory postsynaptic current (EPSC) also showed
that TRPV4 agonist 4α-PDD increased EPSC in hippocampal
slices (Figure A1 in Appendix), indicating that TRPV4 activation
enhances synaptic transmission. Therefore, the enhancement of
NMDAR response or/and increase in glutamate release is likely
involved in TRPV4-mediated neuronal injury during stroke.
TRPV4 forms calcium-permeable, non-selective cation chan-
nels (Plant and Strotmann, 2007). Many studies including ours
have reported that activation of TRPV4R causes an increase in
intracellular calcium (Liu et al., 2007; Plant and Strotmann, 2007).
Reactive oxygen species (ROS) and nitric oxide (NO) are impor-
tant pathophysiological mediators of ischemia-induced toxicity
(Loh et al., 2006). Recent studies performed in the urothelial cells,
human coronary arterial endothelial cells, and lung macrophages
have reported that activation of TRPV4 can stimulate the pro-
duction of H2O2 and NO, which is mediated by TRPV4-induced
increase in intracellular calcium (Donkó et al., 2010; Li et al., 2011a;
Bubolz et al., 2012). Therefore, it is possible that during stroke,
TRPV4 over-activation exacerbates ROS and NO production to
induce neuronal injury.
It has recently been reported that TRPV4 and aquaporin-4
(AQP4) are co-expressed in astrocytic plasma membranes in situ,
as well as in primary cultures and transfected cell lines (Benfenati
et al., 2011). AQP4 plays an important role in keeping water bal-
ance in BBB and is involved in the formation of vasogenic brain
edema (Zador et al., 2009). AQP4 and TRPV4 form a complex
in the astrocytes that is essential for the brain’s volume home-
ostasis by acting as an osmosensor (Benfenati et al., 2011). More-
over, TRPV4 may participate in the pathogenic mechanisms of
astroglial reactivity following ischemic insult because it is involved
in ischemia-induced calcium entry in reactive astrocytes (Butenko
et al., 2012). TRPV4 antagonists increase the viability of astrocytes
in oxidative stress-induced cell damage (Bai and Lipski, 2010). The
experiment performed on primary cultures of human respiratory
epithelial cells shows that TRPV4 mediates calcium influx into
human bronchial epithelia upon exposure to diesel exhaust par-
ticle, which leads to the activation of matrix metalloproteinase-1
(MMP-1; Li et al., 2011a). MMP-2 and MMP-9 are able to digest
the endothelial basal lamina, resulting in opening of BBB. After
cerebral ischemia, levels of MMP-2 and MMP-9 are increased,
which plays an active role in the formation of brain edema and the
secondary brain injury. More experiments will be needed to reveal
a possible involvement of TRPV4 activation and MMPs activation
in ischemia brain. Therefore, TRPV4 over-activation may also be
responsible for the formation of vasogenic brain edema through
facilitating AQP4 function or exacerbating the injury of astro-
cytes or/and basement membrane to increase the permeability of
BBB.
In conclusion, this study shows that activation of TRPV4 poten-
tiates NMDAR response, which may facilitate and prolong the
glutamate excitotoxicity. Therefore, closing TRPV4 may effectively
inhibit [Ca2+]i overload and avoid the side effects through not
directly inhibiting NMDAR. Ischemic injury is a complex insult,
and treatment with a cocktail for multi-target is a more effective
therapeutic strategy. The neuroprotection of TRPV4 antagonist
exhibits long time-window (at least 12 h), which also indicates
that the neuroprotective effect of closing TRPV4 may be medi-
ated through multiple mechanisms. The present study suggests
that TRPV4 is a promising novel target for treatment of ischemic
stroke.
Frontiers in Cellular Neuroscience www.frontiersin.org March 2013 | Volume 7 | Article 17 | 8
Li et al. TRPV4-mediated increase in NMDA-current
ACKNOWLEDGMENTS
This work was supported by National Natural Science Foun-
dation of China (31271206 and 30900577), Science and
Technology Project of Jiangsu Province (BK2009416 and
BK2011029), Basic Medical Advantage Disciplines Project of Nan-
jing Medical University (JX10131801055), and Graduate Stu-
dents Scientific Research Innovation Project of Jiangsu Province
(CXZZ12_0567).
REFERENCES
Bai, J. Z., and Lipski, J. (2010). Dif-
ferential expression of TRPM2 and
TRPV4 channels and their poten-
tial role in oxidative stress-induced
cell death in organotypic hippocam-
pal culture. Neurotoxicology 31,
204–214.
Benfenati, V., Caprini, M., Dovizio,
M., Mylonakou, M. N., Fer-
roni, S., Ottersen, O. P., et al.
(2011). An aquaporin-4/transient
receptor potential vanilloid 4
(AQP4/TRPV4) complex is essential
for cell-volume control in astrocytes.
Proc. Natl. Acad. Sci. U.S.A. 108,
2563–2568.
Bubolz, A. H., Mendoza, S. A., Zheng,
X., Zinkevich, N. S., Li, R., Gutter-
man, D. D., et al. (2012). Activa-
tion of endothelial TRPV4 channels
mediates flow-induced dilation in
human coronary arterioles: role of
Ca2+ entry and mitochondrial ROS
signaling. Am. J. Physiol. Heart Circ.
Physiol. 302, H634-H642.
Butenko, O., Dzamba, D., Benesova, J.,
Honsa, P., Benfenati, V., Rusnakova,
V., et al. (2012). The increased
activity of TRPV4 channel in the
astrocytes of the adult rat hip-
pocampus after cerebral hypoxia/
ischemia. PLoS ONE 7:e39959.
doi:10.1371/journal.pone.0039959
Chen, B. S., and Roche, K. W. (2007).
Regulation of NMDA receptors by
phosphorylation. Neuropharmacol-
ogy 53, 362–368.
Chen, L., Liu, C., and Liu, L. (2008a).
Changes in osmolality modulate
voltage-gated calcium channels in
trigeminal ganglion neurons. Brain
Res. 1208, 56–66.
Chen, L., Liu, C., and Liu, L. (2008b).
The modulation of voltage-gated
potassium channels by an isotonic-
ity in trigeminal ganglion neurons.
Neuroscience 154, 482–495.
Chen, L., Liu, C., Liu, L., and Cao, X.
(2009). Changes in osmolality mod-
ulate voltage-gated sodium chan-
nels in trigeminal ganglion neurons.
Neurosci. Res. 64, 199–207.
Donkó, A., Ruisanchez, E., Orient, A.,
Enyedi, B., Kapui, R., Péterfi, Z., et
al. (2010). Urothelial cells produce
hydrogen peroxide through the acti-
vation of Duox1. Free Radic. Biol.
Med. 49, 2040–2048.
Everaerts, W., Zhen, X., Ghosh, D.,
Vriens, J., Gevaert, T., Gilbert, J. P.,
et al. (2010). Inhibition of the cation
channel TRPV4 improves bladder
function in mice and rats with
cyclophosphamide-induced cystitis.
Proc. Natl. Acad. Sci. U.S.A. 107,
19084–19089.
Garcia-Elias, A., Lorenzo, I. M., Vicente,
R., and Valverde, M. A. (2008).
IP3 receptor binds to and sensitizes
TRPV4 channel to osmotic stimuli
via a calmodulin-binding site. J. Biol.
Chem. 283, 31284–31288.
Kauer, J. A., and Gibson, H. E. (2009).
Hot flash: TRPV channels in the
brain. Trends Neurosci. 32, 215–224.
Kemp, J. A., and McKernan, R. M.
(2002). NMDA receptor pathways
as drug targets. Nat. Neurosci. 5,
1039–1042.
Laurie, D. J., Bartke, I., Schoepfer,
R., Naujoks, K., and Seeburg, P.
H. (1997). Regional, developmental
and interspecies expression of the
four NMDAR2 subunits, examined
using monoclonal antibodies. Brain
Res. Mol. Brain Res. 51, 23–32.
Li, J., Kanju, P., Patterson, M., Chew,
W. L., Cho, S. H., Gilmour, I., et al.
(2011a). TRPV4-mediated calcium
influx into human bronchial epithe-
lia upon exposure to diesel exhaust
particles. Environ. Health Perspect.
119, 784–793.
Li, L., Liu, C., Chen, L., and Chen,
L. (2011b). Hypotonicity modulates
tetrodotoxin-sensitive sodium cur-
rent in trigeminal ganglion neurons.
Mol. Pain 7, 27–32.
Lipski, J., Park, T. I., Li, D., Lee, S.
C., Trevarton, A. J., Chung, K. K.,
et al. (2006). Involvement of TRP-
like channels in the acute ischemic
response of hippocampal CA1 neu-
rons in brain slices. Brain Res. 1077,
187–199.
Liu, L., Chen, L., Liedtke,W., and Simon,
S. A. (2007). Changes in osmolal-
ity sensitize the response to cap-
saicin in trigeminal sensory neurons.
J. Neurophysiol. 97, 2001–2015.
Loftis, J. M., and Janowsky, A. (2003).
The N-methyl-d-aspartate receptor
subunit NR2B: localization, func-
tional properties, regulation, and
clinical implications. Pharmacol.
Ther. 97, 55–85.
Loh, K. P., Huang, S. H., De Silva, R.,
Tan, B. K., and Zhu, Y. Z. (2006).
Oxidative stress: apoptosis in neu-
ronal injury. Curr. Alzheimer Res. 3,
327–337.
Marmarou, A. (2007). A review of
progress in understanding the
pathophysiology and treatment of
brain edema. Neurosurg. Focus 22,
E1-E10.
Mukherjee, K., Sharma, M., Urlaub, H.,
Bourenkov, G. P., Jahn, R., Südhof, T.
C., et al. (2008). CASK Functions as a
Mg2+-independent neurexin kinase.
Cell 133, 328–339.
Mulcahy, N. J., Ross, J., Rothwell, N. J.,
and Loddick, S. A. (2003). Delayed
administration of interleukin-1
receptor antagonist protects against
transient cerebral ischemia in the
rat. Br. J. Pharmacol. 140, 471–476.
Paschen, W. (1996). Glutamate exci-
totoxicity in transient global cere-
bral ischemia. Acta Neurobiol. Exp.
(Wars) 56, 313–322.
Plant, T. D., and Strotmann, R. (2007).
TRPV4. Handb. Exp. Pharmacol.
179, 189–205.
Schmidt-Kastner, R., and Freund, T.
F. (1991). Selective vulnerability of
the hippocampus in brain ischemia.
Neuroscience 40, 599–636.
Shibasaki, K., Suzuki, M., Mizuno, A.,
and Tominaga, M. (2007). Effects of
body temperature on neural activ-
ity in the hippocampus: regula-
tion of resting membrane poten-
tials by transient receptor poten-
tial vanilloid 4. J. Neurosci. 27,
1566–1575.
Simard, J. M., Kent, T. A., Chen,
M., Tarasov, K. V., and Gerzanich,
V. (2007). Brain oedema in focal
ischaemia: molecular pathophysiol-
ogy and theoretical implications.
Lancet Neurol. 6, 258–268.
Sun, H. S., Jackson, M. F., Martin,
L. J., Jansen, K., Teves, L., Cui,
H., et al. (2009). Suppression of
hippocampal TRPM7 protein pre-
vents delayed neuronal death in
brain ischemia. Nat. Neurosci. 12,
1300–1307.
Szydlowska, K., and Tymianski, M.
(2010). Calcium, ischemia and exci-
totoxicity. Cell Calcium 47, 122–129.
Westerberg, E., Deshpande, J. K., and
Wieloch, T. (1987). Regional dif-
ferences in arachidonic acid release
in rat hippocampal CA1 and CA3
regions during cerebral ischemia. J.
Cereb. Blood FlowMetab. 7, 189–192.
Zador, Z., Stiver, S., Wang, V., and
Manley, G. T. (2009). Role of
aquaporin-4 in cerebral edema and
stroke. Handb. Exp. Pharmacol. 190,
159–170.
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or financial relationships that
could be construed as a potential con-
flict of interest.
Received: 30 October 2012; accepted:
09 February 2013; published online: 04
March 2013.
Citation: Li L, Qu W, Zhou L, Lu
Z, Jie P, Chen L and Chen L (2013)
Activation of transient receptor potential
vanilloid 4 increases NMDA-activated
current in hippocampal pyramidal neu-
rons. Front. Cell. Neurosci. 7:17. doi:
10.3389/fncel.2013.00017
Copyright © 2013 Li, Qu, Zhou, Lu,
Jie, Chen and Chen. This is an open-
access article distributed under the terms
of the Creative Commons Attribution
License, which permits use, distribution
and reproduction in other forums, pro-
vided the original authors and source
are credited and subject to any copy-
right notices concerning any third-party
graphics etc.
Frontiers in Cellular Neuroscience www.frontiersin.org March 2013 | Volume 7 | Article 17 | 9
Li et al. TRPV4-mediated increase in NMDA-current
APPENDIX
FIGUREA1 | Effect of 4α-PDD on EPSC in hippocampal slices. EPSCs
recorded from CA1 pyramidal neurons of hippocampal slices before, during
and after 4α-PDD (10µM) application. On the average, EPSC slope was
enhanced 42.1±5.0% by 4α-PDD (n= 8, paired t -test, P < 0.01). EPSC
was evoked by stimulating Schaffer fibers through a constant-current pulse
delivered by a Master-8 Stimulator (AMPI, Jerusalem, Israel). Hippocampal
CA1 neurons were held at -70 mV and perfused with oxygenated bath
solution composed of (in mM) NaCl 126, CaCl2 1, KCl 2.5, MgCl2 1,
NaHCO3 26, KH2PO4 1.25, d-glucose 20, bicuculline 0.01, and TTX 0.1µM.
Pipette solution was composed of (in mM) Cs-gluconate 132.5, CsCl 17.5,
MgCl2 2, EGTA 0.5, HEPES 10, ATP 4, and QX-314
[N -(2,6-Dimethylphenylcarbamoylmethyl) triethylammonium bromide] 5 and
pH was adjusted to 7.2 by CsOH.
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